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ABSTRACT 
 
The purpose of this study was to determine and compare the outcomes of tuberculosis 
(TB) treatment among Human Immunodeficiency Virus (HIV) co-infected TB patients, 
and identify factors associated with these outcomes. A quantitative cross-sectional 
analytic design was used. Patient level secondary data was collected and analysed for 
the study. A total of 575 TB patients, including 360 non-HIV infected, 169 HIV co-
infected and 46 without a documented HIV status, were enrolled. The overall treatment 
success rate was 91.5%, and HIV co-infected TB patients had a high rate (11.8%) of 
unfavourable outcomes. The cure rate was significantly lower (10.1% versus 24.2%) 
and the death rate higher in HIV co-infected patients (8.3% versus 2.5%). Age and TB 
classification were significantly associated with treatment outcome. No association was 
found with starting ART, Cotrimoxazole prophylactic treatment or enrolment in HIV care, 
but 22% of HIV co-infected TB patients were taking ART when they developed TB 
disease. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are among the most 
prevalent communicable diseases afflicting the populations of resource poor countries 
of Africa like Ethiopia (World Health Organization [WHO] 2012a:3). The interaction of 
the two diseases in the same person is associated with adverse individual patient health 
outcomes (Chaisson & Martinson 2008:1089-1092). There is scarcity of evidence on the 
magnitude of the problem and the potential contributing factors that determine these 
outcomes. This is a study designed to generate evidence on the health outcomes of HIV 
infected TB patients and to identify determinants of these outcomes in the Ethiopian 
context. In this dissertation the researcher introduces readers to the background of 
study, problem statement, research design and methods applied in order to achieve the 
objectives stated by the researcher. 
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
TB and HIV are the most prevalent communicable diseases of major public health 
concern in the populations of sub-Saharan African (SSA) countries including Ethiopia. 
Co-infection with HIV and TB is very common with an estimated 30% of HIV infected 
persons having dual infection with TB (Getahun, Gunneberg, Granich & Nunn 
2010:[S202-203]). About 80% of the total estimated disease burden of HIV associated 
TB is found in countries of  SSA, and this part of the world has the “highest rates of 
cases and deaths per capita” attributable to TB disease (WHO 2012a). TB is among the 
leading causes of morbidity and mortality in HIV infected individuals; and in patients with 
TB disease, co-infection with HIV significantly complicates both the diagnosis and 
management of TB disease (Getahun, Gunneberg, Granich & Nunn 2010:[S202-203]). 
 
Many of the countries most severely affected by the two epidemics are resource poor 
settings with weak health systems (Friedland, Churchyard & Nardell 2007:S1-S3). 
Through the technical and financial support of donors and other international 
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development partners, these countries are working to address the problems posed by 
these health issues (WHO 2010b). Decreasing the burden of disease from both 
infections among the population and improving the health outcomes of the individual 
patients attending medical services is of paramount importance to mitigate the adverse 
impact from these conditions.  
 
TB is one of the most prevalent communicable diseases in the world and a major cause 
of morbidity and mortality (WHO 2012a). The WHO estimated that, in 2011, there were 
more than 8.7 million new cases of TB worldwide and that 1.4 million people have died 
of TB disease in that same year (WHO 2012a).The burden of TB disease is highest in 
the resource poor countries of Asia and Africa (Chaisson & Martinson 2008:1089-1092). 
TB is among the top diseases considered as global public health threats, and the WHO 
declared TB a global public health emergency in 1993 (WHO 2012a).  
 
The high prevalence of the HIV in the early 1990s has contributed to the enormous TB 
disease burden globally (Chaisson & Martinson 2008:1089-1092). The geographic and 
population distribution of TB and HIV has shown marked overlap with the highest 
prevalence of both diseases occurring in the populations of the poor countries of the 
sub-Saharan Africa (SSA) and Asia (Chaisson & Martinson 2008:1089-1092). The 
interaction of the two deadly diseases has incurred massive losses to the human 
assets, socioeconomic growth, and overall development of the countries hardest hit by 
these diseases. The global TB report by WHO (WHO 2012a) shows that about 1.1 
million people with TB disease in 2011 (out of the 8.7 million who developed TB in 
2011) were co-infected with HIV, and 79% of these reside in the resource poor 
countries of Africa. There were also 400,000 HIV associated TB deaths in the same 
time period.  
 
Early detection of TB disease and prompt initiation of effective treatment with potent 
anti-TB drug regimens is required to decrease morbidity and mortality from TB disease 
in HIV infected patients (WHO 2012b). This approach also is critically important for 
prevention of transmission of TB within the population.  
 
Co-infection with HIV complicates the diagnosis and management of TB disease and 
greatly increases the mortality risk if both infections are not properly addressed 
(Padmapriyadarsini, Narendran & Swaminathan 2011:850). Therefore, HIV screening 
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among TB patients and routine symptom screening of HIV patients with appropriate 
diagnostic evaluation for those with a positive symptom screen  are critical in settings 
where the two diseases are known to be prevalent (Chaisson & Martinson 2008:1089-
1092). 
 
Most infections with the TB bacilli in immune competent individuals remain 
asymptomatic and become latent infections (Centers for Disease Control and 
Prevention [CDC] 2012c). In contrast, for HIV infected persons, there is an increased 
risk for the development of active TB disease. HIV-infected people who have latent TB 
(asymptomatic TB infection) have a 20-30-fold increased risk of developing active TB 
disease than those who are non-HIV infected (WHO 2011b).  
 
Furthermore, the clinical presentation of TB disease in HIV infected individuals is 
different from those without HIV infection. There is more extra pulmonary presentation 
of TB and non-specific signs, symptoms, and diagnostic features in HIV co-infected TB 
patients (University of California San Francisco [UCSF] 2013). 
 
The presence of other co-morbidities also complicates the diagnosis and management 
of TB in these patients. Treatment of active TB disease in HIV co-infected TB patients is 
complicated due to drug interactions, adverse drug reactions, Immune Reconstitution 
Syndrome (IRS), and other less favourable patient outcomes (UCSF 2013).  
 
Co-infection with HIV is associated with significantly increased likelihood of mortality 
from TB disease, and HIV co-infected TB patients have significantly lower cure rates 
and lower treatment success rates compared to non-HIV infected TB patients (Daniel & 
Alausa 2006:222-226; WHO 2011b). HIV patients with active TB disease have a 
probability of dying of 15–20% at one year while those without active TB disease have 
7–8% probability of dying at one year (Lawn, Myer, Bekker & Wood 2006:1605-1612). 
Early detection and prompt treatment are important in reducing morbidity and mortality.  
 
Provision of Isoniazid prophylactic Treatment (IPT) for those co-infected patients with 
latent TB prevents development of active TB disease (WHO 2011a). Anti-Retroviral 
Therapy (ART) has been associated with a significantly reduced risk of developing 
active TB disease and death from TB (Lawn, Kranzer & Wood 2009:685-699; WHO 
2012a).  
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Ethiopia is one of the countries in SSA that is hardest hit by the TB and HIV epidemics. 
With an estimated national adult prevalence of 1.5%, it is estimated that, in 2013, there 
were 734,048 adults and children infected with HIV in Ethiopia (Ethiopian Health and 
Nutrition Research Institute, Federal Ministry of Health 2012). The incidence of TB was 
258 cases per 100,000 populations in 2011 (WHO 2012a). The prevalence of HIV 
among incident TB cases was found to be 17% (WHO 2012a). This indicates that there 
is a high burden from each disease and a considerable co-infection rate. It is essential 
and timely to better understand how and why HIV co-infected TB patients have 
unfavourable outcomes following anti-TB treatment. It is hoped that gaining a better 
understanding of the reasons for unfavourable outcomes will help identify strategies and 
standards targeted at improving the medical care of HIV co-infected TB patients.  
 
1.3 RESEARCH PROBLEM 
 
There is high TB and HIV co-infection rate among the population in countries of the 
Sub-Saharan African region, and this has major adverse public health impact (Chaisson 
& Martinson 2008:1089-1092; WHO 2012a). Ethiopia is an African country with high 
burden of both diseases (Ethiopian Health and Nutrition Research Institute, Federal 
Ministry of Health 2012; WHO 2012a). There is lack of evidence on the individual 
patient outcomes of co-infected patients with active TB disease receiving anti-TB 
treatment.  
 
According to the Global TB Report by WHO (WHO 2012a), the health systems of most 
countries lack the appropriate monitoring system to track, record, and report individual 
patient outcomes of TB/HIV co-infected patients, and it recommends that “The recording 
and reporting of the outcomes of TB treatment disaggregated by HIV status needs to be 
improved.” It is also necessary for country programmes to have reliable information on 
patient outcomes of co-infected patients to assess progress made towards meeting 
targets set to decrease the number of TB deaths among HIV-positive people (WHO 
2012a; United Nations Development Programme 2014). 
 
TB/HIV co-infected patients have multiple individual, disease specific and treatment 
related factors that can adversely affect their treatment outcomes (UCSF 2013). 
Comparison of the outcomes of co-infected TB patients with those without HIV infection 
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is relevant to understand the magnitude of the problem. Identifying the different factors 
that are associated with these outcomes would provide the evidence for informing the 
designing of relevant standards of care for the co-infected patients. Strategies targeted 
at improving the outcomes of co-infected patients are needed to mitigate the impact of 
the two deadly diseases. This problem lead to the following aim and research questions: 
 
1.4 AIM OF THE STUDY 
 
The aim of this study is to understand and explain the outcomes of TB treatment in TB 
patients with respect to their HIV status and the differences in these outcomes among 
the different groups, and to identify the associated underlying factors that contribute to 
the occurrence of these outcomes. 
 
1.5 RESEARCH QUESTIONS 
 
The researcher formulated the following research questions in order to summarise the 
research problem. 
 
• What is the TB treatment outcome among HIV co-infected TB patients? 
• Is there a difference in TB treatment outcome in HIV co-infected TB patients? 
• What are the risk factors for an adverse TB treatment outcome? 
 
1.6 RESEARCH OBJECTIVES 
 
In this study the researcher wishes to assess the following objectives: 
 
• To assess TB treatment outcomes in HIV co-infected patients in major urban 
setting in Ethiopia 
• To compare the treatment outcomes among HIV co-infected and non-HIV 
infected TB patients 
• To identify determinants of adverse TB treatment outcomes among HIV co-
infected TB patients 
• To make recommendations for developing or revising the national guidelines for 
the management of TB and HIV 
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1.7 DEFINITIONS OF TERMS 
 
In this study, a number of terms are used to identify the different characteristics, 
processes, and outcomes related to the study subjects, settings or methods. The 
definitions of the relevant terms used in the study are provided in this section. 
 
1.7.1 Conceptual definitions 
 
1.7.1.1 Tuberculosis 
 
Tuberculosis  a usually chronic highly variable disease that is caused by a bacterium of 
the genus Mycobacterium (M. tuberculosis) and rarely in the United States by a related 
mycobacterium (M. bovis), is usually communicated by inhalation of the airborne 
causative agent, affects especially the lungs but may spread to other areas (as the 
kidney or spinal column) from local lesions or by way of the lymph or blood vessels, and 
is characterised by fever, cough, difficulty in breathing, inflammatory infiltrations, 
formation of tubercles, caseation, pleural effusion, and fibrosis — called also TB 
(Merriam-Webster Inc. 2013b, Sv "tuberculosis"). 
 
The WHO defined tuberculosis as “an infectious bacterial disease caused by 
Mycobacterium tuberculosis, which most commonly affects the lung [and] is transmitted 
from person to person via droplets from the throat and lungs of people with the active 
respiratory disease” (WHO 2015a). 
 
1.7.1.2 HIV infection 
 
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune 
system, destroying or impairing their function and is transmitted through unprotected 
sexual intercourse (anal or vaginal), transfusion of contaminated blood, sharing of 
contaminated needles, and between a mother and her infant during pregnancy, 
childbirth and breastfeeding (WHO 2015b). 
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1.7.1.3 Co-infection 
 
Co-infection simultaneous infection of a cell or organism by separate pathogens 
(Mosby's Medical Dictionary 2009a, Sv "co-infection"). 
 
It is also described as “when a person is living with more than one infection at a time” 
(CATIE [s.a]). 
 
1.7.1.4 Outcome 
 
The condition of a patient at the end of therapy or a disease process, including the 
degree of wellness and the need for continuing care, medication, support, counselling, 
or education (Mosby's Medical Dictionary 2009b, Sv "outcome"). 
 
The United States Food and Drug Administration (FDA) has further elaborated and 
classified outcome with respect to ‘Clinical outcome assessment’ (COA) which is “any 
assessment that may be influenced by human choices, judgment, or motivation and 
may support either direct or indirect evidence of treatment benefit” (FDA 2015). 
According to FDA, “COAs depend on the implementation, interpretation, and reporting 
from a patient, a clinician, or an observer”. This is in contrast to measurements that use 
automated processes, algorithms etc … to ascertain outcomes (for example, 
biomarkers).  
 
There are four types of COAs in the FDA classification and they are patient-reported 
outcome (PRO) measures, clinician-reported outcome (ClinRO) measures, observer-
reported outcome (ObsRO) measures, and performance outcome (PerfO) measures. 
 
Clinician-reported outcome (ClinRO) — A ClinRO is based on a report that comes from 
a trained health-care professional after observation of a patient’s health condition. A 
ClinRO measure involves a clinical judgment or interpretation of the observable signs, 
behaviors, or other physical manifestations thought to be related to a disease or 
condition. ClinRO measures cannot directly assess symptoms that are known only to 
the patient (e.g., pain intensity). 
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Observer-reported outcome (ObsRO) — An ObsRO is a measurement based on an 
observation by someone other than the patient or a health professional. This may be a 
parent, spouse, or other non-clinical caregiver who is in a position to regularly observe 
and report on a specific aspect of the patient’s health. An ObsRO measure does not 
include medical judgment or interpretation. Generally, ObsROs are reported by a 
parent, caregiver, or someone who observes the patient in daily life.  
 
Patient-reported outcome (PRO) — A PRO is a measurement based on a report that 
comes from the patient (i.e., study subject) about the status of a patient’s health 
condition without amendment or interpretation of the patient’s report by a clinician or 
anyone else. A PRO can be measured by self-report or by interview, provided that the 
interviewer records only the patient’s response. Symptoms or other unobservable 
concepts known only to the patient (e.g., pain severity or nausea) can only be measured 
by PRO measures. PROs can also assess the patient perspective on functioning or 
activities that may also be observable by others. 
 
Performance outcome (PerfO) — A PerfO is a measurement based on a task(s) 
performed by a patient according to instructions that is administered by a health care 
professional. Performance outcomes require patient cooperation and motivation. These 
include measures of gait speed (e.g., timed 25 foot walk test), memory recall, or other 
cognitive testing (e.g., digit symbol substitution test). 
 
Proxy-reported outcome — A proxy is a person who reports an outcome as if she/he 
was the patient him/herself. Proxy reports are not recommended for unobservable 
symptoms that can be known only by the patient. A proxy-reported outcome is not a 
PRO but is a measurement based on a report by someone other than the patient 
reporting as if he or she is the patient. A proxy-reported outcome is not a valid endpoint. 
 
An outcome can also be measured through the use of a biological marker (biomarker) 
which is described as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” (FDA 2015). 
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1.7.1.5 Patient 
 
A sick individual especially when awaiting or under the care and treatment of a 
physician or surgeon (Merriam-Webster Inc. 2013c, Sv "patient"). 
 
1.7.1.6 Treatment 
 
The action or manner of treating a patient medically or surgically (Merriam-Webster Inc. 
2013d, Sv "treatment"). 
 
1.7.1.7 Cure 
 
Remission of signs or symptoms of a disease especially during a prolonged period of 
observation (Merriam-Webster Inc. 2013e, Sv "cure"). 
 
1.7.1.8 Default 
 
To fail to fulfill an obligation or a promise (Mosby's Dental Dictionary, 2008, Sv 
"default"). 
 
1.7.2 Operational definitions 
 
For conducting a proper scientific study, it is critical that data are collected and used 
accurately and reliably by all individuals involved in data collection, compilation, 
summary and/or analysis. That means there should be a uniform and valid 
understanding of all the variables used in the study, and everyone should be collecting 
and managing the data in the same way. For this purpose, operational definitions 
should be made prior to the data collection. “An operational definition describes exactly 
what the variables are and how they are measured within the context of [the] study” 
(Cherry 2014). 
 
“An operational definition, when applied to data collection, is a clear, concise detailed 
definition of a measure” (Operational definition 2014). The following operational 
definitions are adapted from the Ethiopian National Tuberculosis, Leprosy and TB/HIV 
prevention and Control Programme Manual, Guidelines for the clinical and 
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programmatic management of TB, TB/HIV and leprosy in Ethiopia and the Treatment of 
tuberculosis GUIDELINES by the WHO. (Federal Ministry of Health, Ethiopia 2008:52; 
Federal Democratic Republic of Ethiopia Ministry of Health 2013:43; WHO 2010a). 
 
1.7.2.1 TB infection 
 
Infection with mycobacterium tuberculosis bacilli 
 
1.7.2.2 Active TB disease 
 
Presence of signs and symptoms of TB disease in an individual who is infected with 
mycobacterium tuberculosis bacilli. 
 
1.7.2.3 Case of tuberculosis 
 
A definite case of TB (a pulmonary TB case with one or more initial sputum smear 
examinations positive for acid-fast bacilli) or one in which a health worker (clinician or 
other medical practitioner) has diagnosed TB and has decided to treat the patient with a 
full course of TB treatment. 
 
1.7.2.4 HIV infection 
 
Infection with the Human Immune-deficiency Virus (HIV) that is confirmed by approved 
serologic tests. 
 
1.7.2.5 TB/HIV co-infection 
 
The presence of both TB and HIV infection in an individual patient.  
 
1.7.2.6 TB treatment outcome 
 
The final known status of a TB patient who was started on anti-TB treatment. 
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1.7.2.7 Cured 
 
An initially smear-positive patient who is sputum smear-negative at, or one ‘month’ prior 
to, the completion of TB treatment and on at least one previous occasion (usually at the 
end of the 2nd or 5th month). 
 
1.7.2.8 Treatment completed 
 
A patient who completed anti-TB treatment without evidence of failure but for whom 
sputum smear or culture results are not available in the last month of treatment and on 
at least one previous occasion.  
 
1.7.2.9 Treatment failure 
 
A patient whose sputum smear or culture is positive at 5 months or later during 
treatment. Also included in this definition are patients found to harbour a multidrug-
resistant (MDR) strain at any point of time during the treatment, whether they are 
smear-negative or -positive. 
 
1.7.2.10 Defaulter 
 
A patient who has been on treatment for at least four weeks and whose treatment was 
interrupted for 8 or more consecutive weeks 
 
1.7.2.11 Died 
 
A patient who dies for any reason during the course of treatment   
 
1.7.2.12 Transfer out 
 
A patient who started treatment and has been transferred to another reporting unit and 
for whom the treatment outcome is not known at the time of evaluation of treatment 
results. 
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1.7.2.13 Treatment success 
 
The sum of patients who are declared ‘cured’ and those who have ‘completed’ 
treatment. 
 
1.8 RESEARCH PARADIGM 
 
This quantitative cross-sectional study is based on the post-positivist paradigm. The 
main rational behind this philosophy is that it is not possible to make totally independent 
and objective observations of the world (objective reality), but should make all effort to 
get as close to the objective reality as possible, at the same time admitting the inherent 
limitations posed by our own subjectivity and ourselves being part of the reality 
(Introduction to quantitative research 2010). According to the post-positivist view, 
research can never be certain and one cannot fully uncover the objective reality. Rather, 
it emphasises on how much certainty one can have or how much confidence there is in 
predicting or understanding the objective reality.   In this paradigm, "all observation is 
fallible and has error and that all theory is revisable" (Trochim 2006d). It underlines the 
importance of having different measures and/or observations. There could be inherent 
weaknesses in each of these observations and the reconciliation of the different 
approaches may yield the best approximation of the reality or truth (Trochim 2006d).  
 
1.9 STRUCTURE OF THE DISSERTATION 
 
This dissertation is structured in the following manner: 
 
Chapter 1: Study outline 
 
Chapter 2: Literature review 
 
Chapter 3: Research methodology 
 
Chapter 4: Research findings 
 
Chapter 5: Discussions, limitations, recommendations and conclusions  
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1.10 CONCLUSION 
 
There is scarcity of evidence on the TB treatment outcomes of HIV co-infected TB 
patients, particularly so in the Ethiopian context. This is a cross-sectional study 
designed to provide evidence on the different outcomes of TB treatment and potential 
underlying factors that affect these outcomes among HIV co-infected TB patients in the 
Ethiopian context. The findings of the study will have relevance for improving the quality 
of services provided to co-infected TB patients by informing the formulation of standards 
of care that are required in the facilities providing these services. The selection of the 
sites for the study and the retrospective nature of the data collection method may limit 
the validity of the findings of the study. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
In this chapter, the researcher discusses the available body of knowledge, evidence and 
ideas around the research topic from the relevant literature. Literature review is 
described as “a ‘re’-view or ‘further look’ at what has previously been written on a 
particular subject” and is “intended to convey to the reader the current state of 
knowledge on a given subject along with the strengths and limitations of the underlying 
research” (Volmink 2007:66).  The purpose of literature review is justifying planned 
research, contextualising new findings, interpreting the findings of the research, and 
facilitating access to or identifying existing relevant research under the subject being 
studied (Volmink 2007:66-67).  
 
In reviewing the literature for this study, the following terms or concepts have been used 
to search for the relevant published literature on the topic: TB, TB infection, TB disease, 
TB diagnosis, TB treatment, TB treatment outcome, HIV, HIV infection, AIDS and 
opportunistic illnesses, and TB-HIV co-infection. 
 
2.2 TUBERCULOSIS (TB) 
 
This section will describe the existing evidence and context on TB. The different aspects 
of the problem of TB with respect to the clinical and programmatic perspectives will be 
discussed. 
 
2.2.1 TB infection 
 
It is estimated that one third of the world’s population is infected with the Tuberculosis 
bacterium (CDC 2014). TB is one of the most prevalent communicable diseases that is 
caused by a bacterium called Mycobacterium tuberculosis, and is spread from person to 
person through the air (air borne infection) by inhaling the bacteria that are released into 
the air when a person with TB disease of the lungs or throat coughs or sneezes (CDC 
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2012b). Most people who have inhaled the TB bacteria and have become infected can 
fight and control the infection from multiplying and spreading in their body through their 
immune system. These individuals do not have symptom and/or signs of TB disease 
and do not spread the infection to other individuals but the TB bacteria live in their body 
as latent infection without causing disease. However, the latent TB infection can 
reactivate and cause active TB disease in these individuals if their immune system can 
no longer fight the infection due to other concurrent conditions that weaken their 
immunity, for example co-infection with HIV, underlying diabetes mellitus, and advanced 
age. 
 
2.2.2 TB disease 
 
When the TB bacterium multiplies and spreads in the body, it causes TB disease that 
can affect any part of the body but most commonly the lungs (respiratory system), and 
individuals with active TB disease, particularly those with TB of the lungs, transmit the 
TB infection to other individuals (CDC 2012b). People who have TB disease are sick 
and will have symptoms like chronic cough (usually with copious sputum), fever, 
sweating, weight loss, and other symptoms and signs specific to the organs affected by 
the disease.   
 
TB disease continues to be a major global health problem; 8.6 million people worldwide 
are estimated to have developed active TB disease in the year 2012 (1.1 million of 
these were people co-infected with HIV) and approximately 1.3 million of them have 
died from the disease (WHO 2013a). Of these TB associated deaths, 320,000 were 
among those co-infected with HIV. Without effective treatment, TB disease is 
associated with high mortality rates; studies have shown that as high as 70% of smear 
positive TB patients (but not infected with HIV) will die in 10 years’ time (CDC 2014). In 
HIV infected individuals, TB is the leading cause of death (CDC 2012a).  
 
Ethiopia is identified as one of the 22 High Burden Countries (HBC) in the world where 
80% of the world’s TB cases are found (CDC 2013). The WHO global TB report for 
2013 indicated that there were an estimated 230,000 (251 per 100,000) incident cases 
of TB in Ethiopia in 2012. There were an estimated 16,000 TB deaths (17 per 100,000) 
in Ethiopia during the same time period, excluding deaths among those co-infected with 
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HIV. The report also mentions that there were an estimated 23,000 HIV-positive incident 
TB cases in Ethiopia in 2012. 
 
2.2.3 TB diagnosis 
 
The diagnosis of TB disease is made through identification of suspected TB cases, and 
undertaking clinical evaluation and diagnostic tests as appropriate. Symptoms of TB 
disease that are most commonly used to identify suspected TB cases include cough of 
two weeks or more duration, fever, night sweating, and weight loss (Federal Democratic 
Republic of Ethiopia Ministry of Health 2013).  
 
Confirmation of the diagnosis of active TB disease requires different diagnostic methods 
employing bacteriological, molecular, histo-pathological and/or radiological procedures. 
All TB suspects must be investigated using one or more of these methods according to 
the recommendation of nationally adopted standard TB diagnostic algorithms either to 
confirm or rule out active TB disease.  
 
According to the Ethiopian guideline for the management of TB, a “proven case of TB” 
is an individual with two sputum smears or culture positive for Mycobacterium 
tuberculosis while one sputum smear positive is sufficient to confirm the diagnosis of TB 
in HIV positive patients. Any patient with Mycobacterium tuberculosis complex identified 
from a clinical specimen (sputum, cerebrospinal fluid, pleural or peritoneal fluid, joint 
aspirate or biopsy specimens) either by culture or by a newer method such as molecular 
line probe assay is also considered as a proven/definite case of tuberculosis. 
 
2.2.4 TB treatment 
 
For the treatment of patients diagnosed with active TB disease, chemotherapy with a 
combination of medications that are effective against TB bacteria is provided for a 
specified duration. The aims of treatment for TB patients are to cure the TB patient, 
prevent death from active TB or its complications, restore quality of life and productivity, 
prevent or decrease transmission of TB infection, prevent the development and 
transmission of drug resistance, and prevent relapse or recurrence of TB disease 
(Federal Democratic Republic of Ethiopia Ministry of Health 2013).  
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TB patients should receive optimal treatment so that these aims are met. Optimal TB 
treatment rapidly and substantially reduces the number of actively multiplying bacteria, 
cures TB disease, prevents relapse of active TB disease, and prevents the development 
of resistance to the drugs. Treatment of TB patients should include an appropriate 
combination of drugs, be prescribed in the correct dosages, be taken regularly by the 
patient according to the right schedule, and provided and taken for a sufficient period of 
time.  
 
The duration of TB treatment consists of two phases: the intensive phase and the 
continuation phase. The type and number of drugs to be taken by the TB patients and 
the schedule of TB treatment vary depending on the phase of treatment, category of TB 
disease, and other concurrent health or physiological conditions of the patients (Federal 
Democratic Republic of Ethiopia Ministry of Health 2013). 
 
2.2.5 TB treatment outcome 
 
For any person who has been diagnosed with active TB disease and put on a course of 
anti-TB treatment, his/her last known status with regard to the treatment provided 
should be documented and reported. This is the outcome of the patient while on or at 
completion of anti-TB treatment. WHO and national TB programmes use standard 
definitions for the different possible outcomes of TB treatment for TB patients. The 
following TB treatment outcome definitions are taken from the Ethiopian national TB 
programme guideline (Federal Democratic Republic of Ethiopia Ministry of Health 
2013:43).  
 
Cured: A patient whose sputum smear or culture was positive at the beginning of the 
treatment but who was smear- or culture-negative in the last month of treatment and on 
at least one previous occasion.  
 
Treatment completed: A patient who completed treatment but who does not have a 
negative sputum smear or culture result in the last month of treatment and on at least 
one previous occasion.  
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Treatment failure: A patient whose sputum smear or culture is positive at 5 months or 
later during treatment or patients found to harbour a multidrug-resistant (MDR) strain at 
any point of time during the treatment, whether they are smear-negative or -positive.  
 
Died: A patient who dies for any reason during the course of TB treatment.  
 
Defaulter: A patient who has been on treatment for at least four weeks and whose 
treatment was interrupted for eight or more consecutive weeks.  
 
Transfer out: A patient who has been transferred to another recording and reporting 
unit and whose treatment outcome is unknown.  
 
Treatment success: A sum of cured and completed treatments. 
 
2.3 HIV INFECTION 
 
Human immunodeficiency virus (HIV) is a retrovirus that destroys the lymphocyte cells 
called CD4 (cluster of differentiation 4) T lymphocytes in the blood and body, and 
causes acquired immunodeficiency syndrome (AIDS) in humans (Overview of HIV 
2014). HIV was first isolated in 1983, and has two types (HIV-1 and HIV-2) and many 
subtypes (clades); the two types have distinct geographic, epidemiologic and pathologic 
features although both are transmitted by similar routes (Corcoran & Meintjes 2009:3).  
 
HIV is transmitted from an infected individual to another individual through 
percutaneous or mucous membrane exposure to infected body fluids like blood, genital 
secretions, and breast milk. The probability of transmission varies based on the type of 
exposure (Kassaye & Levy 2009:39).  
 
There were an estimated 35.3 million people living with HIV throughout the world in 
2012, and there were 2.3 million new HIV infections and 1.6 million AIDS deaths in the 
same year (Joint United Nations Programme on HIV/AIDS 2013). The vast majority of 
these HIV infections and deaths occurred in resource poor countries of sub-Saharan 
Africa. In Ethiopia, there were an estimated 793,700 people living with HIV in the year 
2013 including more than 200,000 children <15 years of age, and there were 
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approximately 45,200 AIDS related deaths in the same time period (Federal HIV/AIDS 
Prevention and Control Office 2014).  
 
The natural course of HIV infection has multiple stages (Maniar, Surjushe & Pande 
2009:133). The initial phase of acute HIV infection becomes clinically manifest within 
about 2-4 weeks of acquiring the virus and has non-specific and variable features that 
may include fever, rash, lymph node swelling, sore throat, all of which gradually subside 
without treatment and are rarely severe enough to lead to a visit to a health care 
provider. Following the acute HIV infection phase, a long period of chronic HIV infection 
sets in whereby there is slow but progressive decline in the individual’s immune 
function. This phase of chronic infection is further classified into early, intermediate and 
late stages. During the early phase of chronic infection, the patient may feel entirely 
normal though may have swollen lymph nodes if carefully examined.  During the late 
stage of HIV infection, there is advanced immune deficiency and deterioration of the 
immune system that predisposes the HIV infected individual to infections and other 
disease conditions, (eg., Tuberculosis, cryptococcal disease, malignancies) (Maniar et 
al 2009:135). 
 
2.4 AIDS AND OPPORTUNISTIC ILLNESSES  
 
The first cases of AIDS were described in the Morbidity and Mortality Weekly Report 
(MMWR) by the United States Centers for Disease Control and Prevention (CDC) in 
1981 about five cases of Pneumocystis Carinii Pneumonia (PCP) among homosexual 
men in Los Angeles, USA (CDC 2001).  
 
The WHO has defined AIDS in adults and children with confirmed HIV infection as 
clinical diagnosis (presumptive or definitive) of any stage 4 condition (see Annex VI); or 
documented CD4 count less than 200 per mm3, or CD4% <15; or among children aged 
12–35 months first ever documented CD4% <20; or among children less than 12 months 
of age CD4% <25 (WHO 2007b).  
 
Opportunistic infections (OIs) are infections that occur because of advanced 
immunosuppression in HIV-infected persons and would not cause illness in non-HIV 
infected persons with intact immune systems (Department of Health and Human 
Services 2013). These infections are more frequent or more severe in HIV infected 
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individuals. Among the most common opportunistic infections that occur in HIV infected 
people are Tuberculosis, Pneumocystis Pneumonia, Toxoplasmosis, and Cyptococcus. 
 
2.5 TB/HIV CO-INFECTION 
 
Co-infection is the “simultaneous infection of a cell or organism by separate pathogens” 
(Mosby's Medical Dictionary 2009, Sv "co-infection"). TB/HIV co-infection is the 
concurrent presence of HIV and TB infection in an individual.  
 
According to recent data from the WHO (WHO 2013b), TB is the most common 
presenting illness among HIV infected individuals coming for care and treatment 
services, and there were an estimated 1.1 million HIV positive new TB cases in 2012 
throughout the world of whom 75% live in the resource-poor countries of the SSA. TB 
accounts for 20% of HIV-related deaths and is unrivalled as the leading cause of death 
among people living with HIV (estimated 320,000 people died of HIV-associated TB in 
2012). Drug-resistant TB including multi-drug resistant (MDR-TB) and extensively drug 
resistant TB (XDR-TB) are emerging threats for HIV co-infected patients that may 
further undermine the TB control efforts in resource-poor countries (Gandhi, Moll, 
Sturm, Pawinski, Govender, Lalloo, Zeller, Andrews & Friedland. 2006:1575-1580). 
 
Among patients with latent TB infection, HIV is the strongest risk factor for TB disease 
progression and is associated with a 20.6-36.7% increased risk compared to HIV 
uninfected people with latent TB (Daley 2009:138). In addition to the increased risk of 
death observed in HIV co-infected patients, there is an increased rate of default and 
recurrence of TB disease in these patients (Daley 2009:143).  
 
Routine programme reports at national programme level and also those reported to 
WHO do not specify TB treatment outcomes disaggregated by HIV status. This is 
clearly described in the 2011 and 2012 WHO Global TB reports. The reports state that 
“most countries with a high burden of TB lacked national or sample [vital registration] 
VR systems and few had conducted mortality surveys. TB mortality among HIV-positive 
people is hard to measure even when VR systems are in place because deaths among 
HIV-positive people are coded as HIV deaths and contributory causes (such as TB) are 
often not reliably recorded” (WHO 2012a). The 2011 global report by WHO further 
states that “Measurements of TB mortality among HIV-positive people from VR data 
remain scarce and are often unreliable. HIV deaths may be miscoded as TB deaths, 
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and TB deaths among HIV-positive people may be impossible to quantify because TB is 
only recorded as a contributory cause of death. About one third of countries submitting 
aggregated VR data on causes of death to WHO do not report data on contributory 
causes. Estimates of TB mortality in HIV-infected individuals thus remain highly 
uncertain” (WHO 2011b).  
 
The same report makes a key recommendation by saying “The recording and reporting 
of the outcomes of TB treatment disaggregated by HIV status needs to be improved, 
using WHO-recommended TB registers (which should also be used by HIV service 
providers including ART clinics)” and further emphasises this with the heading “Better 
reporting of the outcomes of TB treatment by HIV status is urgently needed”.  
 
There is a critical reason for demanding better information on disaggregated TB 
treatment outcomes as stated in the report. In their “Stop TB Partnership,” WHO and 
UNAIDS have set a target of halving the number of TB deaths among HIV-positive 
people by 2015 compared with 2004 (the year in which TB mortality among HIV-positive 
people is estimated to have peaked). To assess whether the goal is achieved, data on 
mortality rates among HIV-positive TB patients during TB treatment are needed. In turn, 
this requires that treatment outcomes for TB patients are disaggregated by HIV status; 
that is, outcomes are available for HIV-positive and HIV-negative TB patients separately 
(WHO 2011b).  
 
According to the WHO Global TB Report for 2013, 96 countries reported TB treatment 
outcomes disaggregated by HIV status for the year 2011, and among the 41 countries 
identified as priority countries, only 19 countries reported disaggregated TB treatment 
outcomes (WHO 2013a). Ethiopia was not among the countries listed as reporting TB 
treatment outcomes disaggregated by HIV status. 
 
A prospective observational study in a high HIV and TB prevalence region in India to 
compare the TB treatment clinical response (patient outcomes) of newly diagnosed 
adult pulmonary TB patients showed that treatment success rates (cured or treatment 
completed) were significantly lower in HIV positive TB patients than in HIV negative TB 
patients (66% vs 85%), and 29% of the HIV positive and 1% of the HIV negative 
patients died during the course of TB treatment (Tripathy, Anand, Inamdar, Manoj,  
Khillare, Datye, Iyer, Kanoj, Thakar, Kale, Pereira & Risbud 2011:521-528). The follow-
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up period for the study lasted for 30 months including 6 months on TB treatment and 24 
months of follow up after completion of TB treatment. During the entire period of 30 
months in the study, 61 (51%) of the 121 HIV positive patients died but there were only 
6 (4%) deaths among HIV negative patients. The study was conducted during the time 
when ART was not available in the region, and none of the HIV positive study 
participants received ART or any form of prophylactic treatment during the study follow-
up period.  
 
A retrospective cohort study in San Francisco, USA, that evaluated treatment outcomes 
in HIV co-infected TB patients demonstrated that significantly more HIV co-infected 
patients died than other TB patients, and HIV co-infected TB patients that were on ART 
during the course of treatment for TB had a significantly lower mortality when compared 
with HIV-infected patients who didn’t receive ART (Nahid, Gonzalez, Rudoy, Jong, 
Unger, Kawamura, Osmond, Hopewell & Daley 2007:1199-1206). In addition, those 
patients who received both TB treatment and ART have a faster sputum smear and 
culture conversion to negative than those not treated with ART. 
 
A study conducted in a large TB treatment centre in Malawi to compare treatment 
outcomes among new smear-positive pulmonary TB patients 15 years of age and 
above, based on HIV status and anti-retroviral treatment (ART) status, showed that HIV 
co-infected TB patients had worse TB treatment outcomes (Tweya, Feldacker, Phiri, 
Ben-Smith, Fenner, Jahn, Kalulu, Weigel, Kamba, Banda, Egger & Keiser 
2013:e56248). In the study, there was a higher likelihood of a successful treatment 
outcome in those HIV co-infected TB patients who were on ART. 
 
A recent Nigerian study from a retrospective cohort of pulmonary TB patients in one 
hospital in Abuja from 2007 to 2012 to determine the differences in TB treatment 
outcome between patients with TB/HIV co-infection and TB patients without HIV 
infection showed that HIV co-infected TB patients have a lower treatment success rate 
(48.8% vs. 78.5%), a higher rate of treatment failure (10.8% vs. 4%), and a higher rate 
of default (38.6% vs. 17%) than TB patients without HIV infection (Ofoegbu & Odume 
2015: 50-56). 
 
Another retrospective review of case records from a tertiary centre in India that 
assessed the treatment outcomes of co-infected TB patients and the factors related to 
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poor outcome indicated that the overall rate of favourable outcome (cured or completed 
treatment) to anti-tuberculosis treatment was 77%, and those with advanced immune 
suppression (CD4<200/mm3) and those on retreatment had unfavourable outcomes that 
include death, failure and default (Sharma, Soneja, Prasad & Ranjan 2014:157).  
 
A retrospective cross-sectional study using routine programme report data to compare 
the outcomes of TB treatment among HIV co-infected and non HIV infected TB patients 
in a province in India found that treatment successes (cured or treatment completed) 
were similar between HIV co-infected TB patients and those who have only TB (Shastri, 
Naik, Shet, Rewari & Costa 2013:4). In this study, while death rates were higher in the 
co-infection group, rates of default and treatment failure were higher among non HIV 
infected TB patients. 
 
To date, in Ethiopia, there is serious lack of data that specifically addresses the issue of 
TB treatment outcomes of HIV co-infected TB patients. A recent retrospective cohort 
study conducted in north-west Ethiopia to identify predictors of mortality among HIV co-
infected TB patients showed that the death rate was 65% lower in TB-HIV co-infected 
patients treated with ART than those not treated with ART (Sileshi, Deyessa, Girma, 
Melese & Suarez 2013:297). But, in the study, direct comparisons with non-HIV infected 
TB patients and data on other TB treatment outcomes is lacking.  
 
Another study with similar retrospective design and looking at a five year cohort of HIV 
co-infected TB patients (from 2009 to 2013) in western part of Ethiopia showed a 
treatment success rate of 60.7% over the five year period (Ejeta, Birhanu & Wolde 
2014:164-171). The results from the study show that there is progressive improvement 
in treatment success rate over the five year period from 12.5% in 2009 to 84.3% in 
2013. The study identified receiving HIV care, co-trimoxazole and ART as factors 
associated with treatment success. However, similar to the other study, there was no 
comparison of the treatment outcomes with non-HIV infected TB patients. The study 
used a small sample size and also considered the outcome ‘transfer-out’ as a negative 
outcome (which may not be the case for many patients). 
 
A retrospective study that assessed the “trend of TB and treatment outcomes” in the 
Gambella region of Ethiopia in the five year period from 2006 to 2010 showed that 
63.4% were ‘successfully treated’, 22.9% defaulted their treatment, 3.6% had died,  
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0.09% had treatment failure and 10% were transferred out to other health facilities 
(Demeke, Legesse & Bati 2013:130). The study identified patient age above 15 years 
and the gender of the patients to be associated with treatment success, but it did not 
look at HIV status of the study participants and had no description of their treatment 
outcomes by HIV status. 
 
This literature review includes very relevant studies from high disease burden and 
resource limited settings. It has focused on the published data most importantly from 
sources that represent the geographic and population profiles of the settings where HIV 
infection and TB disease are highly prevalent. The studies are observational and most 
of them are retrospective in design. The review includes studies both from the pre-ART 
era when HIV co-infected TB patients were not receiving interventions for treating the 
HIV virus or other concurrent opportunistic illnesses, and also from recent time periods 
and settings where provision of ART and management of any associated illnesses (for 
co-infected TB patients) is the standard practice, including prophylactic treatment for 
opportunistic illnesses. It includes a balanced and appropriate mix of study designs, 
settings and delivered services, and looked adequately into the existing evidence to 
enable a fair judgement of what is already known regarding the research questions 
posed. 
 
Other studies that evaluate the outcome of TB treatment were excluded from the 
literature review because either their main focus is on programmatic aspects, like mode 
of service delivery (for example Directly Observed Treatment), method of TB case 
finding, improving tracking of treatment outcomes etc…, or they do not include 
disaggregation and comparison by HIV status when evaluating TB treatment outcome. 
Some studies that looked at TB treatment outcome were focused narrowly on specific 
issues like hospitalization, or only a sub-set of TB patients (for example, patients with 
pulmonary TB or extra-pulmonary TB). These studies were also excluded because the 
specific research questions and the findings they are looking for are significantly 
different from the ones in this study. 
 
This study attempts to address key questions on TB-HIV co-infected patients who have 
been put on a course of anti-TB treatment. Similar to the studies described above, the 
study will determine the TB treatment outcome among HIV co-infected TB patients, and 
identify any differences in treatment outcome in comparison with non-HIV infected TB 
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patients. In addition, the study will look for other factors (other than HIV) that are 
potentially associated with the adverse patient outcomes among HIV co-infected TB 
patients. Unlike some of the studies mentioned above, since a wide range of 
comprehensive HIV care and treatment services are currently available in Ethiopia, the 
HIV co-infected TB patients in the study would have received other related HIV care and 
treatment services including ART, co-trimoxazole prophylactic treatment, adherence 
support, nutritional support and other indicated services.  
 
2.6 CONCLUSION 
 
This literature review has elaborated on the wide range of concepts and existing 
evidence on TB/HIV co-infection and outcomes of TB treatment. Based on this review, 
various programme reports and some studies on TB treatment outcomes have indicated 
that the health outcomes of TB/HIV co-infected individuals have been adversely 
affected by the presence of HIV even after efficacious treatment of TB disease. 
However, there is lack of reliable data from resource poor countries to fully understand 
the current scale of the problem and the contributing factors to the unfavourable 
outcome observed in this group of patients. It is critical to understand the differences in 
health outcomes among co-infected and non-HIV infected TB patients, and identify 
potential contributing factors for these adverse outcomes. This proposed study will 
attempt to address this knowledge gap and potentially inform formulation of strategies 
and standards of care that will improve the health care service delivery and patient 
outcomes in HIV co-infected TB patients. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHOD 
 
 
3.1 INTRODUCTION 
 
In this chapter, the research paradigm, the research design and methods used in the 
study are discussed. A quantitative, non-experimental, cross-sectional, analytic design 
is used to conduct the study. The study population, the sources for the study data, the 
sampling techniques and procedures, the data collection tool, and the characteristics of 
the tools will be described. The types of data analysis, and the tools and procedures for 
the analysis are outlined. In addition, ethical issues concerning the study are also 
addressed. 
 
3.2 RESEARCH PARADIGM  
 
The research paradigm for this research is the post-positivist paradigm which underlines 
that it is not possible to make totally independent and objective observations of the 
world (objective reality), but should make all effort to get as close to the objective reality 
as possible, at the same time admitting the inherent limitations posed by our own 
subjectivity and ourselves being part of the reality (Introduction to quantitative research 
2010). According to the post-positivist view, research can never be certain and one 
cannot fully uncover the objective reality. Rather, it emphasises on how much certainty 
one can have or how much confidence there is in predicting or understanding the 
objective reality.  In this paradigm, "all observation is fallible and has error and that all 
theory is revisable" (Trochim 2006d). It underlines the importance of having multiple 
measures and/or observations which have different types of error inherent to each of 
them, and using ‘triangulation’ of the information from these multiple sources to reach 
close to the objective reality. It recognizes that there could be inherent weaknesses in 
each of the different observations and the reconciliation of the different approaches may 
yield the best approximation of the reality or truth (Trochim 2006d). 
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In considering this research paradigm for this study, as will be discussed in the following 
sections, the researcher recognises the limitations that are inherent in selecting the 
study sites purposefully, the accessible population used for the study which may have 
their own unique characteristics in health seeking behaviour, and the fact that 
determining HIV status of the study participants relies on voluntariness and availability 
of the services at the time of receiving medical care which have been happening before 
the beginning of the study. Therefore, this study will provide its own share of evidence 
to reach to the truth or objective reality in answering the research questions posed to 
respond to the research problem. It also emphasises that other methods and sources of 
data, using different settings, and possibly a combination of quantitative and qualitative 
design will contribute significantly to attaining greater objectivity and answering the 
research questions satisfactorily. 
 
3.2 RESEARCH DESIGN 
 
A structured approach employed by investigators to answer a specific research question 
is referred to as research design, and the design determines the sampling techniques 
and the collection and analysis of the study data (Morroni & Myer 2007:77). The 
objectives of the research and the specific research questions expected to be answered 
by the research determine the choice of the research design. The type of research 
design chosen has implications regarding the ethical issues involved in conducting the 
research and also on the cost of the research. The research design for this study is a 
quantitative, non-experimental, cross-sectional, analytic design. The aspects of this 
design are briefly described in sub-sections below. 
 
3.2.1 Quantitative aspect of design 
 
This study has a quantitative research characteristic. Quantitative research designs are 
employed to determine the relationship between variables within a defined population 
(i.e. look at cause and effect), and randomly selected samples (with larger sample sizes 
that are representative of the target population) are studied with the research data 
gathered through precise measurements using structured and validated data-collection 
instruments (Quantitative Methods 2014). In quantitative studies, there are clearly 
defined research questions at the conception of the studies and the investigator seeks 
objective answers to these questions. In this type of design, selected specific variables 
  
28 
are studied, and the data analysis is performed to identify statistical relationships. The 
study data are in the form of numbers and statistics, and are often presented in tables, 
charts, figures, or other non-textual forms. Throughout the study process objectivity by 
the researcher is required and all forms of bias are to be avoided. The most common 
objectives of quantitative research are to describe, explain, &/or predict phenomena. 
The study findings are commonly reported statistically with correlations, comparisons of 
means, and statistical significance of findings. The results of a quantitative study design 
are generalizable and can be applied to other populations or settings. This study 
compares outcomes of TB treatment and attempts to identify predictors of the 
differential outcomes among randomly selected study participants using objective 
research methods. A pre-designed and validated data collection instrument (Annex V) is 
used to obtain the study data, and data analysis is performed to make comparisons, 
assess correlations, and test statistical significance.  
 
3.2.2 Non-experimental aspect of design 
 
In non-experimental or observational study designs, the researcher observes or 
measures the presence or occurrence of exposure and outcome, but does not introduce 
any form of intervention (Morroni & Myer 2007:77). In this study there is no intervention 
introduced by the researcher, and all exposure and outcome variables to be used in the 
study are captured as they existed or happened during the time frame selected for the 
study. 
 
3.2.3 Cross-sectional aspect of design 
 
A cross-sectional study design is aimed at determining the frequency (or level) of a 
particular attribute, such as a specific exposure, disease or any other health-related 
event, in a defined population at a particular point in time; i.e. the required information is 
obtained from or about the population or the study participants at a fixed point in time 
(Silva 1999:213-214). Cross-sectional studies can also attempt to go further than just 
providing information on the frequency (or level) of the attribute of interest (ex. disease 
outcome) in the study population by collecting information on both the attribute of 
interest and potential risk factors (predictors) such as socioeconomic status, 
intravenous drug use, sexual behaviour, etc. Therefore, cross sectional study designs 
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can be used to investigate and/or analyse associations between an attribute of interest 
and other underlying risk factors. 
 
In this study, information on outcomes (of TB treatment) and potential risk factors 
(exposures) are collected at one point in time. The study attempts to investigate 
associations between outcomes and other risk factors among the study participants in 
the comparison groups. 
 
3.2.4 Analytic design 
 
Analytic aspect of the design enables the researcher to examine potential association or 
relationship between an exposure and an outcome (Morroni & Myer 2007:79). In this 
study, there is comparison of two groups of TB patients (HIV infected versus HIV non-
infected) to assess for any differences in treatment outcomes among the two groups 
and to identify potential predicting factors responsible for the differences. Information on 
underlying risk factors (exposures) and outcomes of TB treatment for both comparison 
groups is collected. This information is used to analyse any associations between the 
outcomes and any of the exposure variables (risk factors). 
 
3.3 RESEARCH METHOD 
 
The research method relates to the systematic procedures employed in selecting the 
study sample, collecting data, analysing the data and addressing ethical issues relevant 
for conducting the study. The different components of these procedures are described 
below.  
 
3.3.1 Population 
 
The group to which the results of the study will be generalised to is called the study 
population and consists of all the subjects one wants to study (Trochim 2006c). The 
target population for this study is all patients diagnosed with active TB disease and put 
on anti-TB treatment regimens. The accessible population is all patients diagnosed with 
active TB disease and put on anti-TB treatment regimens in the selected health facilities 
for this study (see Annex VII for list of selected health facilities). The listing of the 
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accessible population from which the study sample is drawn is called the sampling 
frame (Trochim 2006c). 
  
The data source for this study is the TB register (Annex IV) at the TB clinics of the 
health facilities (health centres and hospitals) where all patients diagnosed with active 
TB disease are put on anti-TB treatment regimens and monitored throughout the course 
of their treatment. The TB registers in the TB clinics of these health facilities are used to 
record all relevant patient level and clinical information for the treatment and monitoring 
of TB patients, and also for reporting of patient level data based on the national 
guidelines. Therefore, the sampling frame for this study is the list of all TB patients 
enrolled (within the selected time frame for the study, which is January 2013 – 
December 2013) in the selected health facilities at which the study is conducted.  
 
3.3.2 Sampling 
 
Sampling is the process of selecting a subset (group of subjects) of the population of 
interest, and this subset is meant to represent the entire population from which it is 
selected (Yount 2006:1). This representative subset of a population is called a sample. 
 
A simple random sampling method is used to enrol eligible study participants into the 
study. The number of study participants to be enrolled from each selected health facility 
is determined proportionally (based on patient load). A table of random numbers is used 
to select and enrol study participants into the study sample from the sampling frame at 
each health facility. 
 
Inclusion criteria 
 
• Any individual who has been diagnosed with active TB disease based on the 
Ethiopian national TB guidelines recommendations. 
• He or she has been started on a course of anti-TB treatment regimen within the 
time frame of the study period. 
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Exclusion criteria 
 
• Any individual who has taken less than four weeks of the course of anti-TB 
treatment regimen. 
• Individuals less than 15 years of age at initiation of anti-TB treatment. 
 
The study sites (health facilities) included in this study are selected based on 
convenience (geographic accessibility) and patient load among all health centres within 
the Addis Ababa city administration which is a major urban setting and capital of 
Ethiopia. Based on the current TB patient load at each site and the number of patients 
required to meet the sample size, eight health facilities are selected (by convenience) 
for conducting the study. The reason for selecting the study sites on convenience is due 
to the limited time available to conduct the study and the challenges of logistics to 
access potential study sites that would be selected by random sampling method. This is 
a limitation of the study which can affect the external validity of the study findings (i.e. its 
generalizability).  
 
Sample size 
 
The sample size calculation is done using the Epi Info 7 statistical software program. 
Since this is a cross-sectional study and comparison is made in the TB treatment 
outcomes between HIV co-infected TB patients and non-HIV infected TB patients, the 
estimated or known proportion of the outcomes for both groups (from similar studies or 
reports etc.) is taken into consideration to calculate the sample size. The prevalence of 
HIV in incident TB cases in Ethiopia was estimated at 17% (WHO 2012a).The reported 
TB treatment success rate for year 2009 indicated in the 2011 WHO global TB report 
(2011b) shows a TB treatment success rate of 72% and 88% for HIV co-infected and 
non-HIV infected TB patients respectively. Using these background data as inputs to the 
epi info 7 statistical software to calculate the sample size, the smallest sample size 
required for this study is 350 TB patients (61 HIV co-infected, 289 non HIV infected) with 
a two sided confidence level of 95% and a power of 80%. 
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3.3.3 Ethical issues related to sampling 
 
In this study, only the individual patient information and clinical data that were obtained 
during routine medical care provision and had been recorded in the TB clinic registers 
are abstracted. The abstracted data pool includes only anonymous data without any 
personal identifiers. No additional information beyond what has already been gathered 
during the medical care of the study participants is collected. All study participants have 
completed their treatment follow-up and have received the standard of care based on 
the national guidelines recommendations by the time they are enrolled in to the study. 
All data and information collected are handled only by the data collector (s) and the 
investigator, and are securely protected. All data are held confidentially and will not be 
used or shared outside the scope of the study. All paper and electronic formats for 
collecting and processing the research data are kept in a secured locked place, and 
electronic formats are password protected. This is done to avoid loss of confidentiality of 
their personal information and to make sure that there is no risk or harm to study 
participants as a result of their enrolment and participation in the study. 
 
The final version of the study protocol has been submitted and ethical clearance 
obtained from the local IRB (Annex I) and the UNISA College of Human Sciences 
(CHS) Health Studies Higher Degrees Committee (HSHDC) [Annex III] prior to 
commencement of the study. Permission is secured from the head of the selected 
facilities (sites) for conducting the study prior to the commencement of the data 
collection for the study (Annex II).  
  
The findings of the study will be shared with the health workers and management team 
of the health facilities where the study was conducted, and other implementing partners 
and donors that support the TB/HIV activities in the facilities and the region. It will also 
be shared with the health governing bodies at regional and national level as appropriate 
including at national technical working groups. The information gained through the study 
will be used to improve the delivery of quality medical care services for all TB patients. 
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3.3.4 Data collection 
 
3.3.4.1 Data collection approach and method 
 
A data collection tool that is pre-designed to capture the relevant individual patient level 
data is used to abstract data from the TB registers (Annex IV). There is no interaction 
with study participants. All data collected have already been obtained during routine 
patient care and recorded in the TB register. The information collected in this data 
collection tool is subsequently transferred to another data entry electronic data sheet 
prepared specifically for the purpose of the study.  
 
3.3.4.2 Development of the data collection instrument 
 
A data collection tool that is designed to capture all relevant information and/or variables 
for the study is developed. This tool was designed in such a way that all patient level 
and clinical data can be abstracted and entered into the tool easily, clearly and 
completely. The tool is in paper format for ease of use at the selected sites. An 
electronic format is used to enter the data for analysis after the data collection has been 
completed.  
 
3.3.4.3 Characteristics of the data collection instrument 
 
In this study, for the purpose of collecting the required study data, a data collection 
instrument or tool has been developed by the researcher (Annex V). This tool or 
instrument is developed based on the standard TB registers that are available at the 
eligible sites to be included in the study. The data to be collected is secondary data that 
was extracted and documented on the TB registers during the process of routine 
medical care provision to these patients by the health care providers at these sites. The 
data collection instrument is designed to capture these data from the TB registers. Each 
variable (ex. HIV status, TB category etc.) has a separate space and a box or place 
where the appropriate response is made. In this way, each variable pertaining to the 
study participants’ baseline characteristics, disease specific data, medical care 
received, and the outcome and relevant time-line with respect to starting and 
terminating medical care and/or follow-up can be abstracted. For each variable all 
possible values are accounted for and avoid additional measurements, approximations 
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or inferences. The tool is completed by marking on the given boxes after each 
applicable given value or documenting a value (ex. age or date). It is simple to use, and 
all variables are easily understood.  
 
3.3.4.3.1 Validity of the data collection instrument 
 
Validity is “the extent to which a measurement instrument actually measures what it is 
meant to measure” (Katzenellenbogen & Joubert 2007:117). An instrument is valid only 
to the extent that the value or score allows making appropriate assessment or inference 
about a specific group of subjects and for specific purposes (Siegle [s.a.]). Among the 
different concepts in evaluating validity, content validity and face validity of the tool were 
evaluated.  
 
Content validity is whether “the measure accounts for all the elements of the variable or 
concept being investigated” (Katzenellenbogen & Joubert 2007:120). The data 
collection tool for this study captures baseline demographic information, HIV and TB 
disease specific and medical care specific patient level data, and TB treatment outcome 
data. This information is the basis for the objectives in this study and is adequately 
accounted for in the tool. Two experts in the field of TB/HIV were given the tool for 
review. They agreed that the tool can account for all the variables required under the 
objectives of the study.  
 
Face validity is “the extent to which the measure … makes sense to those 
knowledgeable about the subject” (Katzenellenbogen & Joubert 2007:120). Experts 
working in TB programme and TB medical care have been consulted during the 
development of this protocol and the data collection instrument. All of the experts gave 
the opinion that the overall study is a relevant and timely undertaking, and the data 
collection instrument also can effectively accomplish the task for which it is designed. 
 
3.3.4.3.2 Reliability of the data collection instrument 
 
The classical test theory states that any observed score or value obtained by a 
measuring instrument or tool consists of both the “true” score and “error” in the 
measurement process; therefore, reducing error in the measurement process is the 
main focus in developing a valid measuring instrument or tool (Kimberlin & Winterstein 
  
35 
2008:2277). The degree of similarity of the results of repeated measurements by a 
measurement instrument or tool (ex. on the same item, subject or group) is the reliability 
or precision of the measuring instrument or tool (Katzenellenbogen & Joubert 
2007:117).  
 
Poor reliability of a measuring instrument can be decreased or improved by identifying 
and addressing the source of the variation between measures. Pretesting or pilot testing 
of a measuring instrument helps to identify and rectify these sources of variation thereby 
refining the instrument and minimising measurement error (Kimberlin & Winterstein 
2008:2277).  
 
In this study, there is no direct data collection from study participants. All data collected 
are secondary data that are already collected and documented by health providers 
during medical care of the TB patients. The tool to collect these data serves as data 
collection check-list to abstract this secondary data. A copy of the data collection tool 
and the standard TB register were shared with a statistician (a consultant in a 
university) for his assessment of the tool and to establish Cronbach alpha score to 
measure the reliability of the tool. Following his recommendation, the researcher did a 
pre-test of the tool by abstracting 15 patients’ entries in the TB register (which are not 
part of the study) to make sure that the check list collects what is intended to be 
collected and check for consistency.  
 
The pre-test showed that the tool can collect the intended data and was 100% 
consistent on repeated measurements. The statistician recommended that it is not 
necessary or applicable to measure the reliability coefficient as the tool is not used for 
primary data collection. Furthermore, data collected from patient information available in 
medical records are generally considered more objective “because the reliability and 
validity of the measures are known, with the error margins and reporting of results 
meeting generally rigorous standards” (Kimberlin & Winterstein 2008:2277). Therefore, 
the data collection tool for this study is found to be reliable. 
 
3.3.4.4 Data collection process 
 
The TB registers are used as the sampling frame. The sample is selected from the TB 
registers using simple random sampling of the TB patients in the register within the 
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appropriate time frame. A table of random numbers is used for randomly selecting the 
study participants from the TB registers. The sampling interval is determined based on 
the patient load at the respective health facility. For those study participants randomly 
selected using this method, the data collectors abstract the required data from the TB 
registers to the data collection tool. At the end of each day of data collection, the data 
collectors check the data for completeness. 
 
3.3.5 Data analysis 
 
The collected study data is entered to an excel sheet and subsequently imported to 
Statistical Package for Social Sciences (SPSS) (PASW Statistics 18) statistical software 
for analysis. Data checking is conducted for any errors, missing or strange values and 
implausible results. Exploratory data analysis using tables and charts is done to further 
understand the data and detect errors and strange values. Then, the data is 
summarised and analysed using the statistical software.  
 
Descriptive data is summarised and presented using tables and charts. Odds ratios are 
calculated for the different groups and sub-groups. Comparison of TB treatment 
outcomes is performed for HIV co-infected and non-HIV infected individuals (and also 
between subgroups if appropriate) using chi-square test to see if observed differences 
between the two groups are significant. Fischer's exact test is used if the numbers in the 
2X2 table are very small (where the chi-squared test is not valid). Logistic regression is 
used to look at associations between individual patient demographic and clinical 
characteristics and TB treatment outcomes. 
 
3.4 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
3.4.1 Internal validity 
 
The internal validity of a study is how much confidence will be there to allow choosing 
among different possible or alternative explanations for the observed results (Trochim 
2006b). That is the degree with which it avoids confounding.  
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In enrolling study participants in to this study, the investigator includes in the sampling 
frame all patients in the selected facilities who meet the inclusion criteria. Study 
participants are selected randomly using a table of random numbers and the number of 
participants from each site is allocated proportional to patient load. The inclusion criteria 
are broad enough to enable enrolling most of the TB patients in the facilities selected for 
the study. This enhances the internal validity of the study by avoiding the selective 
exclusion of TB patients during sample selection.  
 
3.4.2 External validity 
 
External validity refers the generalisability of the findings of the study.  This is the 
degree to which the conclusions made in the study would be applicable to other settings 
like different geographic area, populations or time periods (Trochim 2006a). 
 
In this study, an adequate sample size is used based on estimations from sample size 
calculations to maximize the external validity of the study findings. The sample size is 
calculated based on the expected proportions (of outcomes) under each study group of 
patients. Probability sampling method is used to select the study participants.  
 
3.4 CONCLUSION 
 
This study is designed to generate evidence on the health outcomes of HIV infected TB 
patients after a course of standard TB treatment in selected health facilities within the 
Addis Ababa city administration in Ethiopia. The health outcomes of these co-infected 
TB patients is compared with that of the non-HIV infected TB patients and the 
investigator attempts to identify determinants of any differential outcomes among the 
two groups in the Ethiopian context.  
 
The study has a cross-sectional design and existing data from TB registers in the 
selected facilities are used. Data are abstracted from these registers by trained data 
collectors and there is no interaction with the study participants. The sites that 
participate in this study are selected purposefully but the selection of individual study 
participants is through probability sampling.  
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The data are checked for errors and entered into appropriate statistical software for 
analysis. The data analysis includes descriptive presentation of the data and also 
further statistical analysis for identifying associations among the different variables and 
outcomes. The results of the study will be shared and/or disseminated to the 
participating sites, the local health governing bodies, stakeholders, and other relevant 
forums as appropriate. 
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND  
DESCRIPTION OF THE RESEARCH FINDINGS 
 
 
4.1 INTRODUCTION 
 
This chapter describes the process and findings of the analysis of the data collected for 
the study from the TB registers in the eight TB clinics where the study participants had 
been following their medical care. The investigator discusses the data management 
process, the baseline characteristics of the study participants, and the findings in the 
data analysis with respect to the objectives of the study. The objectives of the study are: 
(1) to assess TB treatment outcomes in HIV co-infected TB patients; (2) to compare the 
treatment outcomes among HIV co-infected and non-HIV infected TB patients; and (3) 
to identify determinants of adverse TB treatment outcomes among HIV co-infected TB 
patients. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
There were eight purposefully selected health centres in Addis Ababa that were 
included as sites for this study. The sites were selected based on patient load and 
accessibility. The investigator went to the respective health facilities (health centres) 
that were selected for the data collection and presented the support letter (Annex II) he 
received from the Ethical Clearance Committee of the Regional Health Bureau (RHB) to 
the head of each facility to gain access to the TB registers at these sites. The head of 
the respective health facilities granted access to the TB clinics (where TB patient 
registers are located) and advised the health workers at the TB clinics to facilitate and 
support the investigator in collecting the data required for the study. 
 
The TB registers used in the TB clinics of Ethiopian health facilities are paper based 
tools and completed manually by the health workers at the TB clinics. They contain the 
demographic and medical (disease, treatment and outcome) information of all TB 
patients attending the specific health facility over a long (up to two years or more) period 
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of time. Since the study participants that are to be enrolled in to the study have already 
completed their course of TB treatment and medical care by the time of the data 
collection and the required data for the study has already been collected and 
documented at the TB registers in the course of the medical care of the study 
participants, a waiver for the informed consent of the study participants has been 
already obtained from the local IRB. The investigator requested for the TB register that 
was used during the study period (January – December 2013) at each of the selected 
facilities. The registers were never removed from the site and remained in an isolated 
and private area within the TB clinic throughout the data collection process. At the end 
of the data collection, the TB registers were returned intact to the health worker at the 
TB clinic of the health facility on the same day. No part of the register or any of the 
content was copied or photographed. The data collection tool was used to abstract the 
required data without any personal identifiers. 
 
The investigator identified the appropriate TB registers at the TB clinics in the selected 
sites and marked the list of TB patients that had been enrolled in the registers within the 
time frame of the study period (i.e. beginning of January 2013 to end of December 
2013). The TB clinics used the Ethiopian calendar in the registers which is different from 
the European calendar on the dates and year count. The investigator used the 
Ethiopian calendar used in the TB registers to identify the 12 months of the study 
period, and there was no drawback encountered in using this approach. TB patients are 
enrolled in the TB register sequentially with unique TB numbers (Annex IV). The TB 
register was used as a sampling frame to randomly select the study participants. The 
investigator used a table of random numbers to select and enrol the study participants 
into the study. Those study participants who were found not to fulfil the inclusion criteria 
were excluded from the study sample. 
 
The investigator used the prepared data collection tool to collect the data of randomly 
selected study participants from the TB registers. Each selected study participant was 
given a code and no personal identifiers were collected. The tool worked very well in 
capturing the required data. The health workers at each site supported the data 
collection by clarifying some ambiguous and/or missing data in the registers. The 
collected data were checked for completeness and accuracy at the end of the data 
collection process at each site (using 5% of the collected data and cross-checking with 
the TB registers).  
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The collected data were transferred to an electronic format (Excel sheet) that was 
prepared to capture the study variables from the data collection tool. The data in the 
Excel electronic format were cleaned. Those study participants with missing data were 
identified. Study participants without documented TB treatment outcome data (<1% of 
the sample) were excluded from the study sample as their data cannot be part of the 
analysis. The most common missing data were baseline HIV status. The commonest 
reason for undocumented HIV status was unavailability of HIV test kits at the time of 
enrolment to TB treatment. There was very limited information on patients who declined 
to be tested for HIV. These study participants with missing HIV status information were 
kept with the study sample to be part of the data analysis.   
 
The investigator imported the cleaned data to SPSS statistical software (PASW 
Statistics 18) from the electronic Excel format. The continuous variable age was 
recoded into age groups for the purpose of the analysis. The treatment outcome was 
also recoded into two groups. The treatment outcomes ‘Cured’ and ‘Treatment 
completed’ were grouped together as favourable treatment outcomes or treatment 
success. The other treatment outcomes were put together as unfavourable treatment 
outcomes. The following sections discuss the findings of the analysis using tables and 
graphs as appropriate. 
 
4.3 RESEARCH RESULTS 
 
Under this part, the findings of the study analysis will be presented including the 
baseline characteristics of the sample, the disease specific and TB treatment specific 
patient level information of the study participants, and the results of the analysis. 
 
4.3.1 Sample characteristics 
 
In this section, the baseline characteristics of the study participants at the beginning of 
their course of treatment will be presented. 
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4.3.1.1 Age distribution 
 
The age of the study participants ranged from 15 years to 90 years with 58.3% in the 
25-49 age range. Table 4.1 shows the age distribution of the sample. 
 
Table 4.1 Age distribution of study participants (N=575) 
 
Age group (years) Number Percentage 
15-24 151 26.3 
25-34 184 32.0 
35-49 151 26.3 
50-64 60 10.4 
64-90 29 5.0 
Total 575 100.0 
 
4.3.1.2 Gender distribution 
 
Male gender accounted for more than half of the study sample as depicted in the pie 
chart below. 
 
 
Figure 4.1 Gender distribution of the study sample (N=575) 
 
4.3.1.3 HIV status of the study participants 
 
Among the 575 study participants enrolled in the study sample, 529 (92%) of them had 
a documented HIV test offered and performed at or prior to the beginning of their course 
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of anti-TB treatment. Almost one-third of the study participants have documented HIV 
co-infection (i.e. HIV positive). This is in contrast to the country report for Ethiopia for 
2013 (WHO 2014b) which shows that 71% of TB patients with known HIV status and 
11% of these being documented as HIV positive. 
 
Table 4.2 HIV status of the study participants (N=575) 
 
HIV status Number Percentage Percentage among tested 
Non-reactive (HIV-
negative) 
360 62.6 68.1 
Reactive (HIV-
positive) 
169 29.4 31.9 
Missing (not done) 46 8.0 0.0 
Total 575 100.0 100.0 
 
 
4.3.2 TB disease characteristics of the study participants 
 
The characteristics of the TB disease in the study participants with respect to the 
standard categories and disease classification are described in this section. 
 
4.3.2.1 TB disease classification 
 
Most of the study participants were diagnosed with pulmonary tuberculosis (55.8%) and 
a quarter of all cases of TB were found to have smear-positive pulmonary tuberculosis 
(P/pos). Extra-Pulmonary (EP) cases accounted for 44% of the total. Figure 4.2 depicts 
the TB disease classification among the study sample. 
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Figure 4.2 TB disease classification of the study participants (N=575) 
 
4.3.2.2 TB treatment category 
 
The majority of the study participants were new TB patients who started their TB 
treatment at the health facility where they have completed their course of TB treatment. 
Twenty patients (3.5%) were put on TB treatment either due to relapsed smear positive 
pulmonary TB (R), TB treatment failure at the end of the course of TB treatment (F), or 
re-started on TB treatment after defaulting on their treatment (D). Table 4.3 depicts the 
distribution of the different categories of TB treatment of the study participants. 
 
 
Table 4.3 Category of TB treatment of the study participants (N=575) 
 
Category Number Percentage 
Default 2 0.3 
Failure 1 0.2 
New 488 84.9 
Other 51 8.9 
Relapse 17 3.0 
Transfer-in 16 2.8 
Total 575 100.0 
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4.3.3 Other medical care services received by the study participants 
 
For those study participants who have co-infection with HIV, other medical services are 
available and recommended as part of the management of their underlying HIV infection 
and other associated illnesses. Enrolment in HIV care will enable the study participants 
to receive relevant HIV care and support services as dictated by their overall health 
status, for example adherence counselling, nutritional support, screening and treatment 
or prophylaxis for other opportunistic diseases, etc. Prophylactic treatment with co-
trimoxazole is part of the standard of care for HIV co-infected patients receiving TB 
treatment. It is also recommended that all HIV patients with active TB disease and on a 
course of TB treatment be started on anti-retroviral treatment (ART). Figure 4.3 shows 
the documented status of the study participants with respect to the provision of these 
medical services. 
 
 
Figure 4.3    Status of other medical care services received by the study 
participants who have co-infection with HIV (N=169) 
 
4.3.4 Treatment outcomes of the study participants 
 
Analysis of the study data demonstrates that the outcome of TB treatment for the study 
participants shows a very high overall treatment success rate (91.5%) defined as either 
‘Cured’ or Treatment completed’ after a course of anti-TB treatment. The treatment 
success rate among all new TB patients was 92.2%, and it was 93.6% among non-HIV 
infected TB patients. The treatment success rate among HIV co-infected TB patients 
was 88.2%. This finding persists at 91.9% treatment success rate even after excluding 
  
46 
those study participants with unknown HIV status. Table 4.4 shows the rate of the 
different treatment outcomes in the study.  
 
Table 4.4  Outcomes of TB treatment in the study participants (N=575) 
 
Treatment outcome Number Percentage 
Cured 106 18.4 
Treatment completed 420 73.0 
Defaulted 15 2.6 
Died 27 4.7 
Failure 7 1.2 
Total 575 100.0 
 
A prospective observational study in a high HIV and TB prevalence region in India had 
shown a treatment success rate of 66% for HIV co-infected TB patients compared to 
85% in non-HIV infected TB patients (Tripathy et al 2011:521-528). Another 
retrospective review of case records from a tertiary center in India also showed an 
overall treatment success rate of 77% (Sharma et al 2014:157). The reported TB 
treatment success rate for year 2009 indicated in the 2011 WHO global TB report (WHO 
2011b) shows a TB treatment success rate of 72% and 88% for HIV co-infected and 
non-HIV infected TB patients, respectively. From global TB reports by the WHO, the 
best treatment success rates (95%) were reported from China among all new TB 
patients (WHO 2014b). The reported treatment success rate for Ethiopia among all new 
TB cases in 2012 was 91%, which is the highest reported yet for this country and shows 
a progressively improving trend over the years (WHO 2014b). The same report 
indicates that the treatment success rate for Ethiopia was less than 80% in the years 
prior to 2011. 
 
The reason for the high treatment success rate observed in this study could be due to 
the fact that the study participants for this particular study were selected from health 
centres which usually provide TB treatment and other medical care services for clinically 
stable patients. Those patients who are seriously sick and with advanced stage of their 
illnesses are referred to hospitals, and they receive their treatment at these referral 
facilities. This could have overestimated the favourable outcomes (treatment success) 
demonstrated in this study. 
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4.3.5 TB treatment outcomes in relation to HIV status 
 
HIV co-infected TB patients have a treatment success rate of 88.2%. The analysis of TB 
treatment outcome disaggregated by HIV status shows that HIV co-infected TB patients 
have a higher rate (11.8%) of unfavourable treatment outcomes (defined as death, 
default or failure) compared to those without underlying HIV infection (6.4%) as shown 
on Table 4.5. This difference was found to be statistically significant using the Chi-
Square test (Table 4.6). This finding is consistent with programme reports from 
countries that show differences in treatment outcomes between those TB patients co-
infected with HIV and those without HIV infection. According to the global TB report 
(WHO 2014b), globally in 2012, HIV co-infected TB patients had 74% favourable 
treatment outcomes compared with 88% for HIV-negative TB patients, though the 
difference was smaller in the African region (75% in co-infected versus 83% in non-HIV 
infected). 
 
Table 4.5 Comparison of TB treatment success based on HIV status (N=529) 
 
TB treatment 
outcome 
HIV status Total HIV negative HIV positive 
Unfavorable outcome 23 (6.4%) 20 (11.8%) 43 (8.1%) 
Favorable outcome 
(treatment success) 337 (93.6%) 149 (88.2%) 486 (91.9%) 
Total 360 (100.0%) 169 (100.0%) 529 (100.0%) 
 
 
Table 4.6 Chi-Square test for treatment outcome comparisons based on HIV 
status 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson chi-square 4.567a 1 .033   
Continuity correctionb 3.867 1 .049   
Likelihood ratio 4.321 1 .038   
Fisher's exact test    .040 .027 
N of valid cases 529     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 13.74. 
b. Computed only for a 2x2 table 
 
The cure rate among HIV co-infected TB patients was significantly lower and the death 
rate significantly higher than that among those without underlying HIV infection (10.1% 
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versus 24.2% and 8.3% vs 2.5%, respectively). Figure 4.4 shows the different outcomes 
of TB treatment in the study participants in relation to their HIV status. The Chi-Square 
test showed that the observed differences in cure and death rates are statistically 
significant (Table 4.7 and 4.8). Very similar findings were reported in the TB global 
report (WHO 2014b) which showed the proportion of TB patients that died during 
treatment was more than three times higher among HIV-co-infected TB patients (11% 
versus 3.4%). According to this report, in the African Region, HIV-co-infected TB 
patients were twice as likely to die as HIV-negative TB patients (10% compared with 
5%). 
 
 
Figure 4.4 Comparisons of treatment outcomes by HIV status 
 
 
Figure 4.5 Comparison of adverse outcomes by HIV status 
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Table 4.7 Comparison of treatment outcomes and HIV status 
 
Treatment 
outcome HIV - HIV + OR 95% CI P value 
Cured 87 (24.2%) 17 (10.1%) 2.702 1.542-4.735 0.001 
Defaulted 10 (2.8%) 3 (1.8%) 1.76 0.476-6.505 0.397 
Died 9 (2.5%) 14 (8.3%) 0.339 0.143-0.805 0.014 
Failure 4 (1.1%) 3 (1.8%) 0.704 0.155-3.192 0.649 
Treatment 
completed 250 (69.4%) 132 (78.1%)    
 
4.3.6 Other characteristics associated with treatment outcome 
 
Further analysis of the study data was performed to identify other factors (variables) that 
potentially affect the outcome of TB treatment in the study population using binary and 
multinomial logistic regression analytic methods. This analysis showed that age and TB 
classification are significantly associated with TB treatment outcome. Table 4.9 provides 
a detailed account of the results of the analysis. No association was observed between 
TB treatment outcome and receiving other medical care services like starting ART, co-
trimoxazole prophylactic treatment or enrolment in HIV care. These findings are in 
contrast to results of other studies from other settings which showed that TB patients 
who were put on ART had more successful treatment outcomes than those not taking 
ART (Tweya et al 2013:e56248; Vijay, Kumar, Chauhan, Narayan Rao & Vaidyanathan 
2011:e21008).  
 
A similar study in HIV co-infected TB patients in Italy showed that there is a marked 
reduction in death rate in patients who were taking ART during tuberculosis treatment; 
but patients who were already on ART when they were diagnosed to have tuberculosis 
had higher risk of death (Girardi, Palmieri, Angeletti, Vanacore, Matteelli, Gori, 
Carbonara & Ippolito 2012:1-8). Looking at HIV co-infected patients separately, the 
analysis shows that there were 37 patients (22%) who had been on ART for more than 
six months when they developed active TB disease. The occurrence of active TB 
disease in those HIV patients who have been on ART for more than six months could 
indicate emergence of treatment failure on the ART regimen. This could have 
dampened the positive effect of ART on TB outcomes. However, a separate analysis 
comparing the TB treatment outcomes among those who developed active TB disease 
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while taking ART for more than six months with the other study participants (who started 
ART after TB diagnosis or were taking ART less than six months when developing 
active TB disease) failed to show a significant difference in TB treatment outcome 
between them (OR=0.613 [0.218-1.726]; P=0.354). 
 
Table 4.8 Results of the binary regression analysis of the association of 
baseline individual, TB disease and other medical care services 
characteristics with TB treatment outcome 
 
Variable Value 
TB treatment outcome 
Total OR 95% CI P value No 
success Success 
Age 
15-24 9 (6.0%) 142 (94.0%) 151 0.243 0.079-0.747 0.014 
25-34 15 (8.2%) 169 (91.8%) 184 0.34 0.120-0.965 0.043 
35-49 10 (6.6%) 141 (93.4%) 151 0.272 0.090-0.820 0.021 
50-64 9 (15%) 51 (85%) 60 0.676 0.215-2.124 0.503 
65-90 6 (20.7%) 23 (79.3%) 29    
All 49 (8.5%) 526 (91.5%) 575    
 
Gender 
F 22 (8.3%) 242 (91.7%) 264 0.956 0.531-1.722 0.881 
M 27 (8.7%) 284 (91.3%) 311    
All 49 (8.5%) 526 (91.5%) 575    
 
TB 
classification 
EP 17 (6.7%) 236 (93.3%) 253 0.436 0.22-0.863 0.017 
P/neg 12 (6.7%) 168 (93.3%) 180 0.432 0.204-0.917 0.029 
P/pos 20 (14.2%) 121 (85.8%) 141    
All 49 (8.5%) 525 (91.5%) 574    
 
Enrollment in 
HIV care 
No 3 (20.0%) 12 (80.0%) 15 2.015 0.516-7.864 0.313 
Yes 17 (11.0%) 137 (89%) 154    
All 20 (11.8%) 149 (88.2%) 169    
 
Co-
trimoxazole 
given 
No 7 (17.9%) 32 (82.1%) 39 1.969 0.725-5.344 0.184 
Yes 13 (10.0%) 117 (90.0%) 130    
All 20 (11.8%) 149 (88.2%) 169    
 
ART started 
No 8 (15.4%) 44 (84.6%) 52 1.591 0.608-4.161 0.344 
Yes 12 (10.3%) 105 (89.7%) 117    
All 20 (11.8%) 149 (88.2%) 169    
 
HIV status 
Negative 23 (6.4%) 337 (93.6%) 360 0.508 0.271-0.954 0.035 
Positive 20 (11.8%) 149 (88.2%) 169    
All 43 (8.1%) 486 (91.9%) 529    
 
For those factors that showed significant association on initial analysis, multinomial 
regression analysis was done. The results show that these factors are still significantly 
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associated with outcomes of TB treatment. Table 4.9 summarises the results of this 
analysis.  
 
Table 4.9 Multinomial regression analysis of factors associated with TB 
treatment outcome 
 
Variable 
Value 
TB treatment 
outcome Total OR AOR 95% CI P value No 
success Success 
Age 
15-24 9 (6.0%) 
142 
(94.0%) 151 0.243 0.150 0.041-0.546 0.004 
25-34 
15 
(8.2%) 
169 
(91.8%) 184 0.34 0.185 0.055-0.619 0.006 
35-49 
10 
(6.6%) 
141 
(93.4%) 151 0.272 0.126 0.034-0.468 0.002 
50-64 9 (15%) 51 (85%) 60 0.676 0.389 0.104-1.457 0.161 
65-90 
6 
(20.7%) 
23 
(79.3%) 29     
All 
49 
(8.5%) 
526 
(91.5%) 575     
 
TB 
classification 
EP 17 (6.7%) 
236 
(93.3%) 253 0.436 0.322 0.149-0.697 0.004 
P/neg 12 (6.7%) 
168 
(93.3%) 180 0.432 0.329 0.146-0.744 0.008 
P/pos 
20 
(14.2%) 
121 
(85.8%) 141  
 
  
All 49 (8.5%) 
525 
(91.5%) 574  
 
  
 
HIV status 
Negative 23 (6.4%) 
337 
(93.6%) 360 0.508 0.367 0.178-0.757 0.007 
Positive 
20 
(11.8%) 
149 
(88.2%) 169  
 
  
All 43 (8.1%) 
486 
(91.9%) 529  
 
  
 
4.4 CONCLUSION 
 
This chapter presented and discussed the findings of the analysis of the study data from 
a random sample of 575 study participants that were taken from the eight health centres 
in Addis Ababa. The age of the study participants ranged from 15-90 years of age with 
58.3% of the participants falling into the age groups 25-49, and males accounted for 
more than half of the study sample. Ninety two percent of the study participants had 
documented HIV test result with almost two-third of them tested negative for HIV, but 
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eight percent of the participants have no documented HIV status (i.e. missing data). The 
most common reason for missing HIV status information was lack of testing kits.  
 
With respect to TB disease characteristics, 56% of the study participants had pulmonary 
tuberculosis (PTB), and smear-positive PTB accounted for one-fourth of all TB cases 
among the study sample. The large majority of these patients were newly diagnosed TB 
patients who started their treatment at the respective facility where they were enrolled to 
the study. 
 
The analysis of the outcome of TB treatment for all the study participants showed that 
the treatment success rate (a sum of ‘cured’ and ‘treatment completed’) was 91.5% 
including for those without a documented HIV status. The treatment success rate was 
92.2% for all new TB patients and 93.6% for all non-HIV infected TB patients. HIV co-
infected TB patients had 88.2% treatment success rate. This high treatment success 
rate remained similar (91.9%) when those with missing HIV status information were 
excluded. There was a lower cure rate and a higher death rate for HIV co-infected TB 
patients (10.1% and 8.3%, respectively) compared to those without underlying HIV 
infection (24.2% and 2.5% respectively).  
 
The high rate of treatment success in this study could be attributed to the fact that most 
patients receiving TB treatment in health centre (lower level health facilities) are 
relatively clinically stable and the seriously sick patients are referred to higher level 
facilities. 
 
In addition to co-infection with HIV, age and TB classification (i.e smear-positive PTB, 
smear-negative PTB, Extra-pulmonary TB) were found to be associated with outcome of 
TB treatment. 
 
In the next chapter, a detailed discussion of these findings, their interpretation, 
comparison with evidence from other studies and sources, and the limitations of the 
study will be presented together with recommendations from the study. 
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CHAPTER 5 
 
CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
This chapter provides an overview and summary of the study findings together with the 
interpretation of the findings. Relevant recommendations based on these findings are 
also discussed. In addition, the limitations of the study and their implications regarding 
the validity of the findings are pointed out. 
 
5.2 DISCUSSION OF FINDINGS 
 
In this section, the major findings of the analysis of the study data will be presented, and 
these findings will be interpreted in light of the problem statement, the study questions, 
and existing evidence from the review of the literature. 
 
The age of the study participants ranged from 15 to 90 years and more than half 
(58.3%) of them were in the age groups between 25 and 49 years. More than half of the 
study participants were males. Among the 575 study participants enrolled into the study 
sample, 529 (92%) have a documented HIV test result, among whom about one-third 
(1/3) were HIV-positive. These findings are much higher than that reported for Ethiopia 
for 2013 with just 71% of TB patients having a documented HIV status and only 11% of 
those with documented status being HIV-positive (WHO 2014b). This high rate of testing 
for HIV and high rate of positivity in the study could be due to the fact that the study was 
conducted in the biggest city of the country which has among the highest HIV 
prevalence rates in the country (Ethiopian Health and Nutrition Research Institute, 
Federal Ministry of Health 2012). Being located in the major town, the study sites also 
could have better access to resources for HIV testing supplies compared to other 
remote sites. Shortage of HIV test kits was one of the major reasons for not being 
tested for HIV. Other countries have reported high rates of testing for HIV (98% for 
Rwanda) among TB patients, and very high rate of HIV positivity (74% for Lesotho and 
Swaziland) among those tested for HIV (WHO 2014b). 
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Most of the study participants were diagnosed to have pulmonary tuberculosis (55.8%), 
and a quarter of all cases of TB were found to have smear-positive pulmonary 
tuberculosis (P/pos). Extra-Pulmonary (EP) cases accounted for 44% of the total. The 
largest proportion of the study participants (85%) were new TB patients and had started 
their TB treatment at the health facility where they had completed their course of TB 
treatment. 
 
In this study, among those study participants who had co-infection with HIV (N=169), 
91.1% had been enrolled in HIV care, 76.9% had received co-trimoxazole prophylactic 
treatment and 69.2% had been regularly receiving ART. 
 
There was a very high rate of treatment success observed in this study. Overall, 
treatment success rate was 91.5% for all the study participants. It was 92.2% for all new 
TB patients and 93.6% for all non-HIV infected TB patients. Other similar studies 
conducted in high prevalence settings showed that the highest treatment success rate 
(85%) is observed in HIV non-infected TB patients and overall success rate (for both 
groups combined) is 77% (Tripathy et al 2011:521-528; Sharma et al 2014:157). From 
global TB reports by the WHO, the best treatment success rates (95%) were reported 
from China among all new TB patients (WHO 2014b).  
 
The reported treatment success rate for Ethiopia among all new TB cases in 2012 was 
91%, which is the highest reported yet for this country and showing a progressively 
improving trend over the years (WHO 2014b). The same report indicates that the 
treatment success rate for Ethiopia was less than 80% in the years prior to the year 
2011. 
 
This study is conducted in health centres that manage stable patients in contrast to 
other higher level health facilities (referral hospitals) where seriously sick patients with 
advanced or complicated disease receive medical care. This could be the reason for the 
higher than expected rate of treatment success observed in this study. 
 
TB treatment outcome disaggregated by HIV status shows that HIV co-infected TB 
patients have a higher rate (11.8%) of unfavourable treatment outcomes (defined as 
death, default or failure) compared to those without underlying HIV infection (6.4%). The 
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cure rate among HIV co-infected TB patients was significantly lower than among those 
without underlying HIV infection (10.1% versus 24.2%); whereas, the death rate was 
higher in HIV co-infected TB patients (8.3% versus 2.5%). These findings are consistent 
with the expected outcomes among HIV co-infected patients including observations 
from studies and programme reports. According to the global TB report (WHO 2014b), 
globally in 2012, HIV co-infected TB patients had 74% favourable treatment outcomes 
compared with 88% for HIV-negative TB patients, though the difference was smaller in 
the African region (75% in co-infected versus 83% in non-HIV infected). In this same 
report, there were very similar findings regarding TB patient mortality which showed the 
proportion of TB patients that died during treatment was more than three times higher 
among HIV-co-infected TB patients (11% versus 3.4%). In the African Region, the 
report indicated that HIV-co-infected TB patients were twice as likely to die as HIV-
negative TB patients (10% compared with 5%). 
 
In addition to HIV status, age and TB classification were significantly associated with TB 
treatment outcome in this study. TB patients in the age group above 65 years of age 
had a higher likelihood of “unfavourable outcome” than those in the other age groups. 
Other studies have also demonstrated the association of adverse TB treatment 
outcomes and advanced age. A study conducted in South India (Ananthakrishnan, 
Kumar, Ganesh, Kumar, Krishnan, Swaminathan, Edginton & Gupta 2013:e67288) 
showed that TB treatment outcomes were poor among older TB patients and there was 
an increased risk of unfavourable outcomes in those above the age of 60 years. 
Another study in Delhi, India also showed a significantly higher rate of death and TB 
treatment failure among TB patients older than 65 years of age (Gaur, Dhingra, Rajpal, 
Aggarwal & Meghna 2004:83). 
 
Lower TB treatment success was observed among those patients with smear positive 
pulmonary TB. This is consistent with the results of other studies in similar settings. A 
study in India demonstrated that TB disease classification is significantly associated 
with TB treatment outcome and patients under ‘Pulmonary’ TB classification had 
“unfavourable outcome” (Vijay et al 2011:e21008). Another Nigerian study showed that 
those TB patients with smear positive status at diagnosis (i.e. pulmonary positive TB 
classification) have more adverse TB treatment outcomes (Babatunde, Elegbede, 
Ayodele, Fadare, Isinjaye, Ibirongbe & Akinyandenu 2013:210).  
 
  
56 
The unexpected finding in this study was the absence of association between TB 
treatment outcome and the other medical care services received by HIV co-infected TB 
patients, namely starting ART, Cotrimoxazole prophylactic treatment and enrolment in 
HIV care. These findings are in contrast to results of other studies from other settings 
which showed that TB patients who were put on ART had more successful treatment 
outcomes than those not taking ART (Tweya et al 2013:e56248; Vijay et al 
2011:e21008). A similar study in HIV co-infected TB patients in Italy showed that there 
is a marked reduction in death rate in patients who were taking ART during tuberculosis 
treatment; but patients who were already on ART when they were diagnosed to have 
tuberculosis had higher risk of death (Girardi et al 2012:1).  
 
Additional analysis of the data showed that 22% of HIV co-infected TB patients were 
taking ART for more than six months when they were diagnosed to have active TB 
disease and started on TB treatment. This finding could be indicative of the emergence 
of treatment failure on the ART regimen these patients were taking. This could have 
contributed to dampen the positive effect of ART on TB treatment outcomes. However, 
no difference in treatment outcome was observed between those who developed active 
TB disease while taking ART for more than six months and the other study participants. 
 
5.3 LIMITATIONS 
 
A major limitation of this study lies in the fact that the sites selected for this study were 
selected purposefully by their geographic accessibility and patient load. All the sites are 
within Addis Ababa which is the capital and the largest town of the country. Patients 
from these facilities might have a different profile from patients residing in other parts of 
the country including in socio-economic status, education, proximity to health facilities, 
and access to information, diagnostic and treatment services. The types of the health 
facilities selected for the study were health centres only. This was because of the 
design of the national TB programme to enable TB patients to receive their TB 
medications under direct observation in the health facilities near their residences, and 
higher level health facilities (hospitals) usually refer the patients they diagnose with TB 
to health centres for initiating and following TB treatment. Health centres provide 
medical care to relatively well and stable patients. Patients with advanced disease and 
more complicated clinical conditions are referred and receive care and treatment 
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services at higher level facilities (referral or specialised hospitals). This could have 
selected patients with better prospects for favourable treatment outcome in this study. 
 
However, an adequate sample size was used to achieve enough power to detect 
differences among the groups and achieve statistical significance. The study 
participants were also randomly selected during enrolment in to the study. On the other 
hand, the sample size calculation didn’t take into account the individual factors other 
than HIV that may affect patient outcome in HIV co-infected TB patients. This might be 
the reason for the observed absence of differences in outcome between those taking 
ART and those not taking ART. 
 
Another limitation is that the data collected is retrospective secondary data which in 
some way proved to have some issues with missing and inaccurate data. It was also not 
possible to collect additional patient information that potentially could have importance 
for the analysis. The data collection was restricted to whatever is documented in the TB 
registers. 
 
5.4 RECOMMENDATIONS 
 
It was necessary for the researcher to make recommendations based on the study 
findings. The following recommendations are made in terms of practice, research, and 
education of health care professionals. 
 
5.4.1 Practice recommendations 
 
For patients diagnosed with active TB disease, routine screening for HIV is 
recommended and the results of this study also confirm this fact. As has been observed 
in other studies, early identification of both TB and HIV, and prompt initiation of 
treatment (both TB treatment and ART) gives TB patients the best chance for a 
favourable treatment outcome or treatment success. Patients in older age groups and 
those patients with smear positive pulmonary TB have increased likelihood of 
unfavourable treatment outcome. This group of patients may require more intensive 
evaluation and follow-up to ensure compliance and identify other medical needs they 
might have. It is also recommended to assess and improve the quality of the other 
medical services that are provided to HIV co-infected TB patients. Timely identification 
  
58 
of ART failure and ARV regimen switching could contribute to improved patient outcome 
and reduce the risk of developing TB while on treatment. Optimal provision of quality 
care and support services for HIV co-infected TB patients is required so that these TB 
patients will not succumb to other concomitant illnesses or conditions (ex. malnutrition, 
opportunistic illnesses). 
 
5.4.2 Recommendations for further research 
 
In this study, it was observed that older TB patients and those patients with smear 
positive pulmonary TB have increased risk of adverse treatment outcomes. Further 
studies are required to explore any additional factors that may contribute to the 
unfavourable treatment outcome among this group of patients. It is also important to 
study what additional medical interventions (ex. nutritional support, adherence support 
etc.) may be employed to improve the treatment outcome of these patients.   
 
Provision of additional medical care services to HIV co-infected TB patients did not 
bring any difference in the treatment outcome among the patients in this study. It will be 
worthwhile to assess the quality and timeliness of the delivery of these services and 
identify any gaps so that quality improvement activities can be implemented. 
 
There could be other factors associated with TB treatment outcomes among TB patients 
in general and HIV co-infected TB patients in particular that were not identified in this 
study. Prospective studies that can capture more diverse variables (in addition to what 
is documented in the TB registers only) will be useful to identify these unknown factors. 
Qualitative studies will also contribute to understanding other patient level and health 
service level factors that are affecting the treatment outcomes in TB patients. 
 
5.4.3 Recommendations for education 
 
Training health professionals in recording and analysing data for use at the service 
delivery sites to improve their practice is indispensable. The evidence should be used to 
implement quality improvement activities and guide clinical practice at service delivery 
site level. 
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5.5 CONCLUSIONS 
 
In this study, the review of the TB registers showed that a high proportion of TB patients 
were tested for HIV and there was a very high rate of co-infection with HIV among 
patients with active TB disease who were receiving TB treatment in the health facilities 
selected for the study. In addition, in terms of documents studied or reviewed, there was 
a high treatment success rate among the study participants in this study. However, 
there was a higher likelihood of unfavourable outcomes and increased death rate 
among HIV co-infected TB patients compared with non-HIV infected TB patients. In 
addition to HIV status, age and TB classification were found to be associated with TB 
treatment outcome. No association was observed between the other medical services 
provided to HIV co-infected TB patients and TB treatment outcome, including ART. Of 
note, a significant proportion of these HIV co-infected TB patients had developed active 
TB disease after they had been receiving ART for more than six months. 
 
Prospective quantitative studies and qualitative studies are required to further explore 
additional patient level and service delivery factors that may affect the outcome of TB 
patients.  
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Annex VI.  WHO clinical staging of HIV/AIDS for adults and adolescents with 
confirmed HIV infection 
Clinical stage 1 
 
Asymptomatic 
Persistent generalized lymphadenopathy 
Clinical stage 2 
 
Moderate unexplainedi weight loss 
(<10% of presumed or measured body weight) 
Recurrent respiratory tract infections sinusitis, tonsillitis, otitis media and pharyngitis) 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulceration 
Papular pruritic eruptions 
Seborrhoeic dermatitis 
Fungal nail infections 
Clinical stage 3 
 
Unexplained severe weight loss (>10% of presumed or measured body weight) 
Unexplained chronic diarrhoea for longer than one month 
Unexplained persistent fever (above 37.6°C intermittent or constant, 
for longer than one month) 
Persistent oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis (current) 
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, 
bone or joint infection, meningitis or bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Unexplained anaemia (<8 g/dl), neutropaenia (<0.5 × 109 per litre) 
or chronic thrombocytopaenia (<50 × 109 per litre) 
Clinical stage 4ii 
 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection (orolabial, genital or anorectal 
of more than one month’s duration or visceral at any site) 
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
Extrapulmonary tuberculosis 
Kaposi’s sarcoma 
Cytomegalovirus infection (retinitis or infection of other organs) 
Central nervous system toxoplasmosis 
HIV encephalopathy 
Extrapulmonary cryptococcosis including meningitis 
Disseminated non-tuberculous mycobacterial infection 
Progressive multifocal leukoencephalopathy 
Chronic cryptosporidiosis (with diarrhoed) 
Chronic isosporiasis 
  
Disseminated mycosis (coccidiomycosis or histoplasmosis) 
Recurrent non-typhoidal Salmonella bacteraemia 
Lymphoma (cerebral or B-cell non-Hodgkin) or other solid HIV-associated tumours 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy or symptomatic HIV-associated 
cardiomyopathy 
 
i  Unexplained refers to where the condition is not explained by other causes. 
ii  Some additional specific conditions can also be included in regional classifications (such as reactivation of American 
trypanosomiasis 
[meningoencephalitis and/or myocarditis]) in the WHO Region of the Americas and disseminated penicilliosis in Asia). 
 
Source: WHO CASE DEFINITIONS OF HIV FOR SURVEILLANCE AND REVISED CLINICAL 
STAGING AND IMMUNOLOGICAL CLASSIFICATION OF HIV-RELATED DISEASE IN 
ADULTS AND CHILDREN 2007. 
  
  
Annex VII. List of selected health facilities 
 
Addis Ketema health center  
Bole 17 health Center 
Kazanchis health center  
Kotebe health center  
Semien health center  
Shiromeda health center  
Wereda 9 (Nifas Silk) health center  
Yeka health center  
 
 
